Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BETAMETHASONE DIPROPIONATE

All products: general benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit

8 more in the class list below

Diprosone · DIN 00417246 · 0.05% · Lot

General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health CanadaMarketed · checked 2026-09-19
StatusGeneral benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Write on scriptno code needed; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprosone · DIN 00417246 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-09-15 · brand DIPROSONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1980 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2870 · Verify on the e-Formulary ↗ (DIN 00417246)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00417246). DIN 00417246: Diprosone Raw flags: dinStatus=E, sec3=Y Item: 840600048; group id 836; item number 2032; lccId None; manufacturer id OCI Source form: Lot; strength: 0.05% Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.2100; ministry $0.1980 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00417246 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2870
Interchangeable products
Ratio-Topisone · DIN 00809187 · $0.1980
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

MOMETASONE FUROATE

· 6 products · General benefit · strengths: 0.1% · Cr, Lot, Oint

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DIPROSONE® (betamethasone dipropionate) is indicated for:  the topical management of corticosteroid-responsive dermatoses. Such disorder include: psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, anogenital and senile pruritus. The lotion is formulated to spread easily without adherence to hairy areas to facilitate treatment of dermatoses, such as psoriasis, and seborrheic dermatitis of the scalp. 1.1 Pediatrics Pediatrics: Based on the available data, the safety and efficacy of DIPROSONE® in pediatric patients have not been established. 1.2 Geriatrics Geriatrics: There is no known evidence to suggest that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00060698.PDF PM date: April 7, 2021 Source product: DIPROSONE; DIN 00323071; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.